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Abstract
Improving our understanding of mammalian pancreas development is crucial for the development of more effective cellular
therapies for diabetes. Most of what we know about mammalian pancreas development stems from mouse genetics. We have
learnt that a unique set of transcription factors controls endocrine and exocrine cell differentiation. Transgenic mouse models
have been instrumental in studying the function of these transcription factors. Mouse and human pancreas development are very
similar in many respects, but the devil is in the detail. To unravel human pancreas development in greater detail, in vitro cellular
models (including directed differentiation of stem cells, human beta cell lines and human pancreatic organoids) are used;
however, in vivo validation of these results is still needed. The current best ‘model’ for studying human pancreas development
are individuals with monogenic forms of diabetes. In this review, we discuss mammalian pancreas development, highlight some
discrepancies between mouse and human, and discuss selected transcription factors that, when mutated, cause permanent
neonatal diabetes.
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Abbreviations
ABCC8 ATP-binding cassette transporter subfamily C
member 8
dpc Days post conception
E Embryonic day
GATA4 GATA binding protein 4
hPO Human pancreatic organoid
hPSC Human pluripotent stem cell
NEUROG3 Neurogenin 3
NKX6–1 NK6 homeobox 1
PDX1 Pancreatic and duodenal homeobox 1
RFX6 Regulatory factor X6
SOX9 SRY-box transcription factor 9
wpc Weeks post conception
Scope
During human pancreas development, the orchestration of
differentiation fates and the acquisition of endocrine and
exocrine cell identity depend on the controlled expression of
unique sets of transcription factors. Transgenic mouse models
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s00125-020-05161-0) contains a slide of the
figure for download, which is available to authorised users.






1 Division of Diabetes, Endocrinology & Gastroenterology, Faculty of
Biology, Medicine & Health, University of Manchester, AV Hill
Building, Oxford Road, Manchester M13 9PT, UK
2 Endocrinology Department, Manchester University NHS Foundation
Trust, Manchester, UK
3 Institut Cochin, INSERM, U1016, CNRS, UMR8104, Université de
Paris, 75014 Paris, France
4 Beta Cell Neogenesis (BENE), Vrije Universiteit Brussel,
Laarbeeklaan 103, 1090 Brussels, Belgium
5 Department of Pediatrics, Division of Pediatric Endocrinology,
University Hospital of Brussels, Jette, Belgium
https://doi.org/10.1007/s00125-020-05161-0
Diabetologia (2020) 63:1974–1980
/ Published online: 31 August 2020
in which transcription factor expression can be manipulated
have been key tools in studies to improve our understanding
of pancreas organogenesis. Most of what we have learnt in
mice holds true for humans, based on transcription factor
expression patterns at different developmental stages. In this
review we will discuss some of the differences that have been
described. New tools have become available for refined exper-
iments in which the expression of transcription factors can be
modulated in human models. Stem cells, for example, have
rapidly become a new paradigm for modelling organ develop-
ment and disease. However, the gold standard for determining
the impact of transcription factor perturbation on human
pancreas development remains human gene allelic loss in indi-
viduals presenting with monogenic forms of diabetes. In this
review we do not exhaustively list all transcription factors
important for pancreas development, but we specifically
address selected transcription factors during human pancreas
development, the consequences of transcription factor pertur-
bations on murine and human pancreas development, and
neonatal diabetes as a means of understanding pancreas devel-
opment. We also provide some reflections on therapy in
developmental disorders of the pancreas.
Human pancreas development
Human pancreas specification is evident at ~29 days post
conception (dpc), with detection of the transcription factor
pancreas and duodenal homeobox 1 (PDX1) in the dorsal
foregut endoderm, which is preceded by forkhead box protein
A2 (FOXA2) expression at 27 dpc [1]. In the mouse, PDX1 is
detected slightly earlier, at embryonic day (E)8.5, which
corresponds to ~25–27 dpc in humans [2]. By 30–33 dpc, both
dorsal and ventral pancreatic buds are apparent, marked by the
transcription factors PDX1, SRY-box transcription factor 9
(SOX9), GATA binding protein 4 (GATA4) and NK6
homeobox 1 (NKX6–1) [1]. At this point the buds contain
multiple microlumens, which eventually form the luminal
network of the branched pancreas. Both buds undergo a peri-
od of growth and branching, before fusing at ~37–40 dpc [1].
During this time there is an expansion of multipotent progen-
itors, marked by the presence of SOX9, GATA4 and NKX6–
1. In contrast with the mouse, there is no expression of the
transcription factor NKX2–2 in the early human pancreatic
buds [1, 2]. With this exception, the early stages of human
pancreas development follow a similar course to those in the
mouse. In mice, the very first hormone-secreting cells appear
at ~E9, shortly after pancreas specification (‘primary transi-
tion’). These glucagon-expressing cells are transient and do
not appear to contribute to the established endocrine cell
population [2]. In contrast, there is no evidence of biphasic
endocrine differentiation during human development. The
first insulin-positive cells appear at 8 weeks post conception
(wpc) [1]. This may reflect subtle anatomical differences
between species; a lack of proximity of the paired dorsal
aortae to the early pancreatic endoderm might prevent the
pro-endocrine signals from the aortae that are observed in
mouse [2]. The hallmark of endocrine differentiation in both
mice and humans is the transient expression of the transcrip-
tion factor neurogenin 3 (NEUROG3). In the mouse,
NEUROG3 is first expressed at E9, heralding the primary
transition. Its expression coincides with more prominent endo-
crine differentiation in the mouse at ~E13 (‘secondary transi-
tion’) [2]. In contrast, NEUROG3 is first apparent in the
human pancreas at 8 wpc, expression peaks between 10 and
14 wpc and then declines from ~18 wpc [1, 3]. It is not clear
precisely when NEUROG3 is turned off in humans, but it is
not detected by 35 wpc [3]. By transplanting human fetal
pancreas into the mouse, NEUROG3 was detected in the graft
until at least 19 weeks after transplantation [4]; both these
findings suggest the period of endocrine differentiation is
much longer in humans than in the mouse [5]. The down-
stream mechanisms by which NEUROG3 coordinates endo-
crine differentiation have been elucidated in the mouse [2, 6]
and are overtly similar to those in humans. There are differ-
ences, such as the temporal expression of the transcription
factors MafA and MafB; while MafB expression diminishes
from beta cells postnatally in the mouse, its expression begins
in human fetal pancreas and is sustained in adult beta cells [7,
8]. MafA expression in murine beta cells peaks soon after
birth, whereas its expression continues to increase in juvenile
and adult human beta cells [9, 10]. Thus, adult human beta
cells express both MafA and MafB, while adult mouse beta
cells only express MafA. For a comprehensive review on
human pancreas development that also includes comparisons
with mouse pancreas development, we refer the reader to [11].
Transcription factors and mouse pancreas
development: some outstanding questions
The expression of several pancreas transcription factors has
been experimentally modified by genetic perturbations in
transgenic mice. The knowledge acquired from such manipu-
lations justifies the considerable effort needed to generate
these mice [2]. Pdx1, for example, has been extensively stud-
ied and its deletion in the mouse leads to pancreas agenesis
[12, 13]. This phenotype was first described almost 30 years
ago but the underlying mechanisms by which loss of Pdx1 has
these drastic consequences remain obscure. We know that the
early events that induce pancreatic budding occur in these
mice, and tissue recombination experiments suggest a cell-
autonomous defect in which pancreatic progenitor cells have
lost competence to respond to morphogenic signals from the
pancreatic mesenchyme [14]. However, we lack direct data
demonstrating either decreased or absent proliferation or
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increased death of pancreatic progenitor cells in these mice.
Neurog3 is another well-studied transcription factor, in part
due to the dramatic phenotype of Neurog3-deficient mice,
comprising a total lack of pancreatic endocrine cells, neonatal
diabetes and early postnatal death [5]. Of particular interest is
the contrast between the robust phenotype in Neurog3 null
mice and the heterogenous presentation in people with
NEUROG3 loss-of-function mutations, as described below.
Finally, mice lacking Rfx6, encoding regulatory factor X6, a
target of NEUROG3, fail to generate any of the pancreatic
endocrine cells except pancreatic-polypeptide-producing cells
and present with small bowel obstruction, pancreas hypopla-
sia, albeit inconstant, and early postnatal death [15]. Of inter-
est in the case of RFX6 mutations in humans are the pheno-
typic differences compared with NEUROG3 mutations and
the persistent role of RFX6 in adult beta cells.
Models to study the role of transcription
factors in human pancreas development
Human model systems are preferable to animal models when
studying human physiology and pathology to avoid the possi-
bility of interspecies differences. However, studying the role
of transcription factors in human pancreas development is
more challenging because of a lack of appropriate models.
In recent years, different in vitro models have been developed
and used in studies aimed to increase our understanding of the
impact of transcription factor perturbations on human pancre-
as development. First, the directed differentiation of human
pluripotent stem cells (hPSCs) into pancreatic endocrine and
exocrine cells has become a reliable model for normal cellular
development and a valuable tool for studying pancreatic
diseases (recently reviewed in [16]). For example, hPSCs have
been used to study the function of specific transcription factors
linked to neonatal diabetes. Either mutant cells from patients
suffering from neonatal diabetes have been reprogrammed
[17] or disease-specific mutations have been introduced into
existing hPSC cell lines through genome editing techniques
[18, 19]. In addition, the human EndoC-βH beta cell lines
have been used to study the impact on beta cell function of
mutations in transcription factors found in patients with
neonatal diabetes. Both gain-of-function studies using gene
overexpression [20] and loss-of-function studies using
siRNA-mediated knockdown [21] have been reported. Other
envisioned strategies using this cell line include CRISPR/
Cas9 genome editing to mimic disease-specific mutations.
While such 2D culture systems model cellular differentiation
and are able to pinpoint developmental defects, they are,
however, intrinsically unable to closely recapitulate organ
growth, morphogenesis and the intercellular interactions
between the endocrine and exocrine compartments. The
development of human pancreatic organoids (hPOs) pushes
cell culture methods into 3D and aims to more closely reca-
pitulate in vivo differentiation. Organoids are defined as 3D
structures grown from either hPSCs or tissue-resident
stem/progenitor cells in which organ-specific cells spontane-
ously self-organise into differentiated functional cell types and
at least some functions of the organ are recapitulated [22, 23].
A major advantage of hPOs is that they could be made from
cells with disease-specific mutations. The closer mimicking of
cellular interactions in a 3D culture ofmouse pancreas progen-
itors has already been shown to more faithfully model
exocrine and endocrine differentiation [24]. Methods for
long-term culture of adult mouse pancreas organoids
composed of PDX1+ ductal cells have also been established;
however, endocrine differentiation was extremely limited in
these 3D models [25]. For human cells, protocols for efficient
expansion of fetal and adult duct-like tissue have been devel-
oped, however, again, subsequent differentiation into endo-
crine cells remains suboptimal [26, 27]. While the above-
described models will surely increase knowledge on human
pancreas development, caution remains warranted when
interpreting these results as none of the models perfectly repli-
cates in vivo pancreas development.
Neonatal diabetes: a natural model to study
the role of transcription factors in human
pancreas development
In the following paragraphs, we want to focus on how case
reports or series of neonatal diabetes can be used to dissect the
function of transcription factors during human pancreas devel-
opment. Neonatal diabetes is a rare form of diabetes defined as
diabetes diagnosed before 6 months of age (approximate inci-
dence of 1:100,000 live births). Most babies with neonatal
diabetes present with decreased birthweight (intra-uterine
growth retardation due to fetal insulin deficiency), decreased
fat reserves and low or undetectable C-peptide levels [28].
Neonatal diabetes could be classified according to the impact
of its underlying mutation on aspects of pancreas develop-
ment, from mutations causing complete pancreas agenesis,
mutations that prevent islet formation, mutations that prevent
beta cell development or cause early beta cell death, mutations
that result in beta cells with defective insulin production or
secretion, to mutations in the secreted insulin (Fig. 1).
However, access to the pancreatic tissue of individuals with
neonatal diabetes for post-mortem examination is very limited
and in-depth studies of such pancreases are scarce. Somewhat
over half (~57%) of affected babies have a transient, relapsing
form of neonatal diabetes (TNDM) but in some of these cases
diabetes may recur after a prolonged period [28, 29].
Currently, there is a list of 34 genes linked to permanent
neonatal diabetes mellitus without autoimmune disease,
which includes mutations in genes for 14 transcription factors,
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insulin itself, genes encoding proteins needed for insulin
secretion (ABCC8 and KCNJ11) and genes encoding proteins
implicated in beta cell survival [30]. State-of-the-art genetic
testing can find a genetic diagnosis for 82% of babies with
neonatal diabetes [30]. In the last part of this review, we will
specifically focus on permanent neonatal diabetes mellitus
associated with mutations in three pancreatic transcription
factors. These can be considered as human gene allelic loss
models for studying the role of transcription factors in human
pancreas development.
In 1997, Stoffers and colleagues first linked human pancre-
as agenesis to PDX1 mutations [31] and, later, more studies
confirmed this association [32, 33]. Pancreatic agenesis results
in a clinical phenotype of both endocrine and exocrine defi-
ciency. The clinical presentation of mutations in pancreatic
transcription factors can vary according to the severity of the
mutations and, for PDX1, cases presenting as isolated perma-
nent neonatal diabetes mellitus without [34] or with subclini-
cal exocrine insufficiency [35] have been reported.
Interestingly, monoallelic loss of PDX1 has a strong, negative
impact on the generation of insulin-positive beta-like cells
from hPSCs during in vitro differentiation [18, 36]. This
finding is intriguing as mice that are haploinsufficient for
Pdx1 are reported to develop normally [12, 13], but become
diabetic with age due to decreased beta cell function [37, 38]
and increased beta cell apoptosis [39, 40]. Future studies will
determine whether these results are valid in vivo or merely
reflect an artefact of the in vitro system.
A block in islet and enteroendocrine cell differentiation has
been linked to NEUROG3 mutations, but the human loss-of-
function phenotype is variable, especially in its pancreatic
endocrine aspects. In 2006, three individuals were described
with NEUROG3 mutations giving rise to congenital
malabsorptive diarrhoea with intestinal enteroendocrine cells.
Unexpectedly, these individuals did not have permanent
neonatal diabetes mellitus, despite their severe NEUROG3
mutations, suggesting that an unidentified factor compensated
for the lack of functional NEUROG3 in the human pancreas
[41]. This hypothesis was challenged by a study reporting that
the mutations in these individuals were not null but
hypomorphic [42] and, more recently, biallelic null mutations
in NEUROG3 were discovered in an individual with perma-
nent neonatal diabetes mellitus and intestinal anendocrinosis

























Fig. 1 Developmental classification of permanent neonatal diabetes.
Transcription factors control normal human pancreas development, from
its morphogenesis, through endocrine differentiation, to beta cell devel-
opment and function. Mutations in transcription factor genes such as
PDX1, NEUROG3 and RFX6 are responsible for different forms of
permanent neonatal diabetes, thus, neonatal diabetes could be classified
according to the developmental impact of the transcription factor muta-
tions on pancreas, islet or beta cell formation. Mutations in genes that
encode proteins involved in the machinery of insulin secretion (ABCC8,
KCNJ11) or insulin (INS) itself can also be included in such a develop-
mental classification. Colour scale indicates mutation severity from null
(red) to hypomorphic (blue). This figure was created using Servier
Medical Art (https://smart.servier.com/). Servier Medical Art by Servier
is licensed under a Creative Commons Attribution 3.0 Unported License.
This figure is available as a downloadable slide
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directed differentiation, as little as 10% NEUROG3 was
demonstrated to be sufficient for pancreatic endocrine cell
differentiation [44]. Reconciliation in the field, however,
was short lived as, more recently, two individuals with
biallelic functionally null variants of the NEUROG3 gene
without permanent neonatal diabetes mellitus were reported
[45]. The reason for the difference in pancreatic function
between the NEUROG3 null phenotype in human and mice
remains poorly understood but may lie in subtle differences in
the way NEUROG3 induces cell cycle arrest in pancreatic
progenitors prior to endocrine differentiation [46].
Similarly, mutations in RFX6 also block endocrine differenti-
ation and are associated with permanent neonatal diabetes
mellitus, pancreatic hypoplasia, intestinal atresia and gallbladder
aplasia or hypoplasia [15, 47]. These phenotypic differences
compared with NEUROG3 deficiency are attributed to earlier
expression of RFX6 in the early gut endoderm [15]. Enteric
anendocrinosis, as documented in the case of NEUROG3 loss,
has not been studied in detail for RFX6 loss in humans [48].
When RFX6 was deleted in hPSCs it decreased the efficiency
with which pancreatic progenitors were generated from hPSCs
[18], which is in line with the reduced size of the pancreas in
some of the Rfx6-deficient mice and in people with biallelic
RFX6 mutations [15, 49]. Apart from its role in pancreas devel-
opment, RFX6 is important for the functioning of adult beta cells.
In the human beta cell line EndoC-βH2, RFX6 regulates insulin
gene (INS) transcription, insulin content and secretion and its
knockdown decreased the activity of Ca2+ channels important
for insulin exocytosis [21].Mouse studies that established a regu-
latory role for RFX6 in islet development [50] have also shown
that RFX6 is essential for maintaining the functional identity of
adult beta cells, as it suppresses disallowed genes such as Ldha,
Slc16a1,Pdgfra and Igfbp4 [48]. This effect on beta cell function
has also been found in humans, as heterozygous truncating vari-
ants of RFX6 were found to cause a form of maturity-onset
diabetes of the young (MODY) with reduced penetrance [51].
Conclusions
Pancreas development is regulated by hierarchical gene regu-
latory networks inwhich some transcription factors implicated
in the pathology of permanent neonatal diabetes mellitus are
key players. While many developmental steps are similar in
mice and humans, there are intriguing differences, some of
which we have highlighted. It is important to note that most
of what we know about mammalian pancreas development
stems from mouse genetics. The study of human pancreas
development has benefited from mouse data, but also from
model systems such as directed differentiation of hPSCs and
human beta cell lines. Modelling human disease or develop-
ment, however, is still modelling; while clinical cases of
neonatal diabetes provide us with direct evidence of the
impact of mutations in transcription factors, albeit often only
evidence of the outcome and not of the process we are trying
to understand. Finding a genetic cause for most forms of
neonatal diabetes is currently feasible, but the genetics of
some syndromic forms remain unclear and are thus a chal-
lenge for the future. The recent report of a mutation in the
transcription regulator CNOT1 as a cause of pancreas and
gallbladder agenesis [52, 53], a regulator that had not been
previously identified as important for mouse pancreas devel-
opment, shows that the natural model of human disease still
has interesting insights to offer [54, 55]. The scientific prog-
ress in our understanding of neonatal diabetes has increased
our understanding of more common forms of diabetes, but
hopefully they too will benefit from therapeutic advances. In
the past, transcription factors were not considered targets for
drug development, but the increased understanding of
diseases and transcriptional regulation is enabling the devel-
opment of such therapeutic strategies in other diseases [56].
We cannot expect such strategies to be useful for people with
early and severe developmental defects, such as complete
pancreas agenesis, but they may be able to target less severe
forms of neonatal diabetes with mainly terminal differentia-
tion defects. Neonatal diabetes already has success stories, but
we are keen to add new ones to the good track record.
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